Earnings Results
AnaptysBio (NASDAQ:ANAB) reported quarterly earnings results on November 12, 2026 that fell short of analyst expectations.
The Healthcare company reported earnings per share of $0.11, missing the consensus estimate of $0.51 by $0.40 per share. Revenue came in at $30.3M, missing the estimate of $33.2M.
Company Overview
AnaptysBio's stock moved following the earnings release. The stock currently trades at $45.45 with a market capitalization of $1.5B.
Missing analyst estimates puts pressure on a stock as investors reassess their growth assumptions. The market's reaction to an earnings miss depends heavily on the magnitude of the shortfall, the company's forward guidance, and whether the miss was driven by temporary or structural factors.
The 78% miss relative to consensus estimates is a notable deviation. Earnings surprises of this magnitude often trigger analyst revisions and can influence institutional positioning in the weeks following the report.
Earnings reports are most useful when viewed as part of a trend rather than in isolation. Investors tracking AnaptysBio should compare this quarter's results against both year-over-year figures and sequential performance to identify whether the business is accelerating, stabilizing, or decelerating. The earnings calendar on Smart Investors Daily tracks upcoming report dates across all publicly traded companies.
AnaptysBio Earnings History
| Quarter | EPS Actual | EPS Est. | Surprise |
| Q3 (Nov 2026) | $0.11 | $0.51 | -78.4% |
| Q2 (Sep 2026) | $-0.11 | $-0.46 | +76.1% |
| Q1 (May 2026) | $-1.84 | $-0.66 | -178.8% |
| Q4 (Mar 2026) | $1.58 | $0.92 | +71.7% |
Related Tools: Earnings Calendar | View ANAB Stock Page
Frequently Asked Questions
When does AnaptysBio report earnings?
Check the latest earnings dates on our ANAB earnings page or the Earnings Calendar.
Did ANAB beat earnings estimates?
See the full Q3 results including EPS actual vs estimate on our ANAB earnings page.